Klaria Pharma Holding AB (KLAR) AI Stock Analysis

• Market Cap: €168.25M
• Dividend Yield: N/A
• Average Volume (3M): 401.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: N/A
• EPS Growth: 17.42%
• Country: SE
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.04
• Shares Outstanding: 245,976,150
• 10 Day Avg. Volume: 684,621
• 30 Day Avg. Volume: 401,283
• PEG Ratio: -0.16
• Price to Book (P/B): 12.62
• Price to Sales (P/S): 18.57
• P/FCF Ratio: -3.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ―

Klaria Pharma Holding AB's stock is under significant pressure due to its poor financial performance, characterized by negative earnings and high leverage. The technical analysis offers some support on a longer-term basis but short-term indicators are bearish. Valuation metrics are unattractive with a negative P/E ratio. Overall, the stock's performance reflects substantial financial and operational hurdles that need to be addressed for improvement.

Klaria Pharma Holding AB Business Overview & Revenue Model

Company Description

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.

How the Company Makes Money

Klaria Pharma makes money primarily through the development and commercialization of its proprietary drug delivery products. The company's revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and the direct sale of their medicinal products. Klaria Pharma often collaborates with larger pharmaceutical firms to apply its drug delivery technology to existing medications, enhancing their efficacy and marketability. These collaborations and partnerships are crucial to the company's revenue, as they provide upfront payments, milestone payments, and royalties from product sales. Additionally, Klaria Pharma may engage in research and development contracts that further support its financial growth.

Klaria Pharma Holding AB Financial Statement Overview

Summary

Klaria Pharma Holding AB is facing significant financial challenges, with consistent net losses impacting profitability and cash flow. High leverage and low equity position pose risks to financial stability. The company needs strategic improvements to enhance revenue growth and operational efficiency to achieve a sustainable financial position.

Income Statement

Klaria Pharma Holding AB has struggled with revenue growth, showing a decrease from 2022 to 2023, and then a slight improvement in 2024. The net profit margin remains negative due to consistent net losses. The EBIT and EBITDA margins are also deeply negative, indicating operational challenges. There is a need for significant improvement in profitability.

Balance Sheet

The company's balance sheet shows high leverage with a declining equity base. The debt-to-equity ratio improved slightly in 2024 due to eliminating debt, but the equity ratio remains low at 5.8% in 2024, indicating potential financial instability. ROE is negative due to persistent net losses.

Cash Flow

Free cash flow remains negative, indicating operational cash challenges. The operating cash flow to net income ratio is negative, reflecting inefficiencies in converting income into cash. However, the company has managed to raise financing to maintain liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.09M	2.25M	8.45M	5.87M	6.11M	7.22M
Gross Profit	4.74M	2.25M	8.45M	5.87M	-4.85M	-6.21M
EBITDA	-13.82M	-19.99M	-20.81M	-44.80M	-39.41M	-35.41M
Net Income	-46.02M	-47.75M	-35.78M	-63.77M	-53.53M	-51.44M
Balance Sheet
Total Assets	47.43M	57.27M	72.95M	120.27M	118.31M	132.41M
Cash, Cash Equivalents and Short-Term Investments	2.54M	598.00K	1.25M	16.76M	25.49M	31.25M
Total Debt	0.00	23.07M	18.93M	17.09M	31.72M	10.26M
Total Liabilities	42.88M	53.96M	31.81M	44.19M	48.89M	22.81M
Stockholders Equity	4.55M	3.31M	41.13M	76.08M	69.41M	109.59M
Cash Flow
Free Cash Flow	-31.28M	-11.94M	-3.37M	-49.77M	-24.80M	-35.33M
Operating Cash Flow	-31.28M	-11.94M	-9.06M	-49.73M	-24.80M	-35.30M
Investing Cash Flow	0.00	0.00	0.00	-42.00K	0.00	13.05M
Financing Cash Flow	33.59M	11.27M	-6.46M	41.06M	19.04M	50.56M

Klaria Pharma Holding AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.68
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:KLAR, the sentiment is Positive. The current price of 0.68 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.52, and above the 200-day MA of 0.67, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 74.90 is Negative, neither overbought nor oversold. The STOCH value of 90.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:KLAR.

Klaria Pharma Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANEXA	50 Neutral	€483.96M	-11.75	-48.65%	―	-60.33%	58.04%
ALZCUR	47 Neutral	kr247.07M	―	-90.66%	―	―	15.74%
KLAR	41 Neutral	€168.25M	-2.32	-530.21%	―	―	17.42%
GABA	28 Underperform	kr7.32M	-0.82	―	―	―	72.30%